Adcetris

(Brentuximab vedotin)

ApprovedAntibody–drug conjugate

Brentuximab vedotin is used to treat certain types of lymphomas (blood cancers) and a skin cancer called cutaneous T-cell lymphoma. It works by targeting cancer cells and delivering chemotherapy directly to them.[2] Adcetris is currently approved and in use across 17 indications[4].[1]

Adcetris is one of 250 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Approved.

Indications

165

Total Trials

Active Trials

249

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Non-Hodgkins LymphomaUnknown

LymphomaCompleted

Cutaneous T-Cell LymphomaCompleted

Hodgkins LymphomaUnknown

Mycosis FungoidesRecruiting

Classic Hodgkin LymphomaRecruiting

Diffuse Large B-Cell LymphomaUnknown status

Chronic Lymphocytic LeukemiaActive, not recruiting

Hodgkin LymphomaRecruiting

Relapsed/refractoryActive, not recruiting

Non-Hodgkins LymphomaPreclinical

Unknown

LymphomaApproved

Completed

Cutaneous T-Cell LymphomaApproved

Completed

Hodgkins LymphomaPreclinical

Unknown

Mycosis FungoidesPhase 2

Recruiting

Classic Hodgkin LymphomaPhase 2

Recruiting

Diffuse Large B-Cell LymphomaPhase 3

Unknown status

Chronic Lymphocytic LeukemiaPhase 3

Active, not recruiting

Hodgkin LymphomaPhase 3

Recruiting

Relapsed/refractoryPhase 2

Active, not recruiting

Showing 10 of 17 indications

Competition

Competitive Landscape

375 competitors in Lymphoma

#DrugCompanyPhaseTrials

Adcetris

Pfizer

Approved

79 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Cabenuva

GSK

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Advanced Hodgkin Lymphoma

NCT03517137

Phase 2Recruiting

Lymphoma

NCT05180097

Phase 3Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT04404283

Q1 2027

Phase 2Recruiting

Mycosis Fungoides

NCT05357794

Phase 1/2Recruiting

Diffuse Large B-Cell Lymphoma

NCT03356054

Phase 2Active, not recruiting

Classic Hodgkin Lymphoma

NCT03057795

Clinical

Trials by Indication[1]

Lymphoma79 trials

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Recruiting·UUniversity of Virginia·Phase 2·NCT05404945·44 enrolled

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT01874054·55 enrolled

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Completed·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT02686346·53 enrolled

Show 76 more trials

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

Completed·—·Phase 1/2·NCT01994850·32 enrolled

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting· Takeda logo

Takeda·Phase 4·NCT06831370·124 enrolled

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02927769·72 enrolled

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Completed· Takeda logo

Takeda·Phase 4·NCT01990534·60 enrolled

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT02191930·70 enrolled

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01920932·77 enrolled

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Withdrawn·—·Phase 1·NCT03373305

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Active, not recruiting·—·Phase 2·NCT02758717·46 enrolled

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06377566·71 enrolled

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Completed· Pfizer logo

Pfizer·Phase 3·NCT01100502·329 enrolled

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Completed· Pfizer logo

Pfizer·Phase 2·NCT01716806·131 enrolled

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·—·Phase 1·NCT03013933·29 enrolled

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

Withdrawn·EEric Bernicker, MD·Phase 1·NCT02780011

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Unknown status·NNorthwestern University·Phase 2·NCT01476410·48 enrolled

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Unknown status·NNew York Medical College·Phase 1/2·NCT02098512·20 enrolled

Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas

Completed·SSamsung Medical Center·Phase 2·NCT02280785·33 enrolled

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Completed·UUNC Lineberger Comprehensive Cancer Center·N/A·NCT01578967·41 enrolled

Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas

Completed·SSeoul National University Hospital·Phase 2·NCT02388490·25 enrolled

Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Recruiting·NNational Cancer Center, Korea·Phase 2·NCT05243693·30 enrolled

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Withdrawn·WWestern Regional Medical Center·Phase 1/2·NCT02408042

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 1/2·NCT02243436·67 enrolled

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04745949·31 enrolled

Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT01569204·100 enrolled

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02684292·304 enrolled

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Terminated·MMayo Clinic·Phase 1·NCT02254239·10 enrolled

Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

Unknown status·UUniversity of Modena and Reggio Emilia·Phase 2·NCT02275598·12 enrolled

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01902160·3 enrolled

A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity

Completed·UUniversity of Birmingham·Phase 2·NCT02567851·38 enrolled

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT03646123·255 enrolled

BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

Recruiting·UUniversity of Miami·Phase 2·NCT07002216·48 enrolled

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02292979·170 enrolled

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT00848926·102 enrolled

Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT03474133·80 enrolled

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Completed·—·Phase 2·NCT01393717·57 enrolled

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

Withdrawn·UUniversity of Kansas Medical Center·Phase 2·NCT04334174

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Active, not recruiting·UUniversity of Washington·Phase 2·NCT01703949·28 enrolled

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Unknown status·—·Phase 2·NCT06201507·44 enrolled

Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

Suspended·IInsel Gruppe AG, University Hospital Bern·Phase 1/2·NCT03187210·20 enrolled

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Unknown status·MMarjolein Spiering·Phase 1·NCT02280993·72 enrolled

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

Unknown status·MMultinational Center for Quality of Life Research, Russia··NCT03440788·70 enrolled

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03755804·232 enrolled

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02581631·145 enrolled

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01534078·34 enrolled

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Terminated·NNorthwestern University·Phase 1/2·NCT01805037·20 enrolled

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01771107·41 enrolled

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Active, not recruiting· Takeda logo

Takeda·Phase 2·NCT05673785·52 enrolled

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03138499·23 enrolled

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Unknown status·KKing Abdullah International Medical Research Center·Phase 2·NCT03527628·220 enrolled

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT05180097·84 enrolled

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Recruiting·YYale University·Phase 2·NCT05313243·32 enrolled

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Completed· Takeda logo

Takeda·Phase 3·NCT01712490·1,334 enrolled

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 1·NCT01060904·51 enrolled

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 3·NCT05711628

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT01421667·176 enrolled

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Completed· Pfizer logo

Pfizer·Phase 1/2·NCT02572167·93 enrolled

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02169505·2 enrolled

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Completed·DDeepa Jagadeesh·Phase 2·NCT02588651·23 enrolled

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·—·Phase 2·NCT02744612·39 enrolled

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Active, not recruiting· Takeda logo

Takeda·Phase 1/2·NCT02979522·59 enrolled

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Recruiting· Takeda logo

Takeda··NCT05481437·8 enrolled

Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02227433·20 enrolled

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

Completed· Takeda logo

Takeda··NCT04213209·95 enrolled

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Completed· Takeda logo

Takeda··NCT03729609·113 enrolled

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01508312·66 enrolled

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Recruiting·HHospital Regional de Alta Especialidad del Bajio·Phase 2/3·NCT05595447·20 enrolled

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT01868451·118 enrolled

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

Enrolling by invitation·NN.N. Petrov National Medical Research Center of Oncology·Phase 3·NCT07258680·114 enrolled

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Not yet recruiting·XXiuhua Sun·Phase 4·NCT06761911·100 enrolled

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01900496·6 enrolled

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT01841021·1 enrolled

Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Completed·UUniversity of Cologne·Phase 2·NCT03652441·14 enrolled

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Completed· Pfizer logo

Pfizer·Phase 2·NCT01461538·84 enrolled

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Completed· Pfizer logo

Pfizer·Phase 3·NCT01777152·452 enrolled

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Completed· Takeda logo

Takeda·Phase 1/2·NCT01492088·36 enrolled

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01780662·46 enrolled

Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Pilot Study of the Rare Lymphoma Working Group

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03264131·16 enrolled

Brentuximab Vedotin13 trials

Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly

Withdrawn·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT01671813

A Safety Study of Brentuximab Vedotin in Participants With HIV

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT05244473

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Completed· Pfizer logo

Pfizer·Phase 1·NCT01309789·39 enrolled

Show 10 more trials

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Withdrawn·YYale University·Phase 2·NCT04138875

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02244021·13 enrolled

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Completed· Pfizer logo

Pfizer·Phase 1·NCT01026233·52 enrolled

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT02298283·40 enrolled

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Completed· Pfizer logo

Pfizer·Phase 2·NCT00947856·110 enrolled

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

No longer available· Pfizer logo

Pfizer··NCT01196208

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)

Terminated·MMassachusetts General Hospital·Phase 1·NCT01940796·19 enrolled

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02533570·20 enrolled

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

Terminated·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02499627·43 enrolled

Brentuximab Vedotin for Steroid Refractory GvHD

Completed·MMassachusetts General Hospital·Phase 1·NCT01596218·35 enrolled

Anaplastic Large Cell Lymphoma8 trials

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 1·NCT01950364·20 enrolled

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 4·NCT01909934·50 enrolled

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT00866047·58 enrolled

Show 5 more trials

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Withdrawn·UUniversity of Washington·Phase 1/2·NCT02729961

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Completed· Takeda logo

Takeda··NCT02139592·292 enrolled

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT03205891

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01979536·137 enrolled

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Completed· Takeda logo

Takeda·Phase 2·NCT02939014·39 enrolled

Diffuse Large B-Cell Lymphoma7 trials

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02594163·25 enrolled

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Completed·WWashington University School of Medicine·Phase 1·NCT02086604·37 enrolled

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 1/2·NCT03356054·37 enrolled

Show 4 more trials

A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Active, not recruiting·PPatrick Reagan·Phase 2·NCT02734771·24 enrolled

CD30 Imaging in Diffuse Large B-cell Lymphoma

Unknown status·UUniversity Medical Center Groningen·Phase 3·NCT06186986·20 enrolled

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01925612·87 enrolled

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04404283·240 enrolled

Hodgkin Lymphoma7 trials

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05675410·1,875 enrolled

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Active, not recruiting·CCity of Hope Medical Center·Phase 2·NCT03712202·159 enrolled

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT02505269·34 enrolled

Show 4 more trials

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05922904·25 enrolled

A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma

Active, not recruiting·AAcademic and Community Cancer Research United·Phase 2·NCT03233347·83 enrolled

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Recruiting·UUniversity College, London·Phase 3·NCT04685616·1,042 enrolled

A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

Completed·CColumbia University·Preclinical·NCT01657331·65 enrolled

35 more indications

Mycosis Fungoides5 trials

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Completed·VVirginia Commonwealth University·Phase 1·NCT02822586·5 enrolled

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03587844·58 enrolled

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT05414500·10 enrolled

Show 2 more trials

Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level

Completed·YYoun Kim·Phase 2·NCT01396070·36 enrolled

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05357794·30 enrolled

Cutaneous T-cell lymphoma4 trials

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Completed·FFox Chase Cancer Center·Phase 1·NCT02616965·16 enrolled

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed· Takeda logo

Takeda·Phase 4·NCT05442554·10 enrolled

Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07178457·84 enrolled

Show 1 more trial

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Completed· Takeda logo

Takeda·Phase 3·NCT01578499·131 enrolled

Germ Cell Tumor3 trials

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Completed·FFondazione Michelangelo·Phase 2·NCT01851200·9 enrolled

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Terminated·NNabil Adra·Phase 2·NCT02689219·18 enrolled

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02988843·1 enrolled

Classic Hodgkin Lymphoma3 trials

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT03947255·12 enrolled

A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma

Active, not recruiting·CCity of Hope Medical Center·Phase 2·NCT03057795·62 enrolled

Phase 2 Study of Pembrolizumab With Chemotherapy in Frail Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Recruiting·CCity of Hope Medical Center·Phase 2·NCT07275216·23 enrolled

Recurrent Classic Hodgkin Lymphoma3 trials

A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT01896999·146 enrolled

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma Previously Treated With Brentuximab or Checkpoint Inhibitors

Recruiting·EEmory University·Phase 2·NCT05039073·46 enrolled

A Two Cohort Randomized Study for Patients With High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse

Not yet recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07572123·374 enrolled

Systemic Sclerosis2 trials

Brentuximab Vedotin for Systemic Sclerosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03222492·17 enrolled

Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT03198689·11 enrolled

Relapsed or Refractory2 trials

A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02423291·15 enrolled

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Terminated·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1/2·NCT02462538·3 enrolled

Relapsed/Refractory2 trials

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02497131·25 enrolled

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Active, not recruiting·NNew York Medical College·Phase 2·NCT07013565·20 enrolled

Treatment1 trial

CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.

Completed·IImagine Institute·Phase 2·NCT03217643·14 enrolled

Clinical Pharmacology1 trial

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Completed· Pfizer logo

Pfizer·Phase 1·NCT01026415·73 enrolled

Systemic Mastocytosis1 trial

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Completed·JJason Robert Gotlib·Phase 2·NCT01807598·10 enrolled

Induction Chemotherapy1 trial

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Completed·MMassachusetts General Hospital·Phase 1·NCT01830777·22 enrolled

Newly Diagnosed1 trial

Brentuximab for Newly Diagnosed Hodgkin Disease

Completed·MMitchell Cairo·Phase 2·NCT02398240·40 enrolled

Allogeneic Stem Cell Transplantation1 trial

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

Completed·WWashington University School of Medicine·Phase 1·NCT01700751·17 enrolled

Advanced Cancer1 trial

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated· Pfizer logo

Pfizer·Phase 1·NCT04254107·133 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

BV After Allogeneic Hematopoietic Stem Cell Transplantation

Unknown status·UUniversity Hospital, Caen·Phase 2·NCT03540849·58 enrolled

Acute Graft Versus Host Disease1 trial

Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease

Withdrawn·FFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium·Phase 2·NCT01616680

Advanced Stage1 trial

HD21 for Advanced Stages

Active, not recruiting·UUniversity of Cologne·Phase 3·NCT02661503·1,500 enrolled

Hematologic Malignancies1 trial

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Withdrawn·FFred Hutchinson Cancer Center·Phase 1/2·NCT01620229

Acute Myeloid Leukemia1 trial

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT02096042·1 enrolled

Ann Arbor Stage IIB Hodgkin Lymphoma1 trial

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02166463·600 enrolled

Stage III1 trial

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03907488·994 enrolled

Diffuse Cutaneous Systemic Sclerosis1 trial

An Open Label Extension Study of Brentuximab Vedotin Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma)

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT05149768·3 enrolled

Relapsed Classic Hodgkin Lymphoma1 trial

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab Without Stem Cell Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting·CCity of Hope Medical Center·Phase 2·NCT04561206·31 enrolled

Advanced Hodgkin Lymphoma1 trial

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03517137·150 enrolled

CD30-Positive Neoplastic Cells Present1 trial

Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03007030·25 enrolled

Adult T-Cell Leukemia/lymphoma1 trial

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas

Active, not recruiting·CCity of Hope Medical Center·Phase 2·NCT03113500·48 enrolled

NK-Cell Lymphoma1 trial

Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study

Recruiting·NNew York Medical College·Phase 1·NCT03719105·40 enrolled

Peripheral T-Cell Lymphoma1 trial

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

Completed· Pfizer logo

Pfizer·Phase 2·NCT04569032·82 enrolled

Recurrent Hodgkin Lymphoma1 trial

A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Completed·UUniversity of Washington·Preclinical·NCT02227199·45 enrolled

Lymphomatoid Papulosis1 trial

A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas

Completed·JJohn Reneau·Phase 2·NCT03409432·26 enrolled

Cutaneous T-Cell Lymphoma/Mycosis Fungoides1 trial

A Phase II, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in Patients With CD30-positive Cutaneous T-cell Lymphoma (CTCL)

Not yet recruiting·PPeking University First Hospital·Phase 2·NCT07717580·46 enrolled

Melanoma1 trial

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies

Completed· Pfizer logo

Pfizer·Phase 2·NCT04609566·161 enrolled

Recurrent Follicular Lymphoma1 trial

A Phase II Study of Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular Lymphoma

Recruiting·JJoseph Tuscano·Phase 2·NCT04587687·23 enrolled

Chronic Lymphocytic Leukemia1 trial

ALPINE-2: Zanubrutinib vs Ibrutinib in CLL

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT04795869·652 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 19, 2011

ADCETRIS

NDA BLA125388

Aug 19, 2011

ADCETRIS

BLA BLA125388

Aug 19, 2011

ADCETRIS

NDA BLA125388

Jan 13, 2012

ADCETRIS

NDA BLA125388

Jan 13, 2012

ADCETRIS

NDA BLA125388

Aug 19, 2013

ADCETRIS

NDA BLA125388

Nov 23, 2014

ADCETRIS

NDA BLA125388

Nov 23, 2014

ADCETRIS

NDA BLA125388

Aug 17, 2015

ADCETRIS

NDA BLA125388

Aug 17, 2015

ADCETRIS

NDA BLA125388

Mar 4, 2016

ADCETRIS

NDA BLA125388

Sep 28, 2016

ADCETRIS

NDA BLA125388

Nov 9, 2017

ADCETRIS

NDA BLA125388

Mar 20, 2018

ADCETRIS

NDA BLA125388

Nov 16, 2018

ADCETRIS

NDA BLA125388

Oct 15, 2019

ADCETRIS

NDA BLA125388

Nov 10, 2022

ADCETRIS

NDA BLA125388

Jun 14, 2023

ADCETRIS

NDA BLA125388

Jun 23, 2023

ADCETRIS

NDA BLA125388

Feb 11, 2025

ADCETRIS

NDA BLA125388

Sources

References

[1]
ClinicalTrials.gov — 165 trial records for Brentuximab vedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Adcetris drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Brentuximab vedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Brentuximab vedotin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA125388). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor; Tumor Necrosis Factor Receptor Superfamily Member 8 Binding Agent[3]
Modality: Antibody–drug conjugate[3]
Highest Phase: Approved[1]
Company: Pfizer

Adcetris

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Lymphoma79 trials

Brentuximab Vedotin13 trials

Anaplastic Large Cell Lymphoma8 trials

Diffuse Large B-Cell Lymphoma7 trials

Hodgkin Lymphoma7 trials

Mycosis Fungoides5 trials

Cutaneous T-cell lymphoma4 trials

Germ Cell Tumor3 trials

Classic Hodgkin Lymphoma3 trials

Recurrent Classic Hodgkin Lymphoma3 trials

Systemic Sclerosis2 trials

Relapsed or Refractory2 trials

Relapsed/Refractory2 trials

Treatment1 trial

Clinical Pharmacology1 trial

Systemic Mastocytosis1 trial

Induction Chemotherapy1 trial

Newly Diagnosed1 trial

Allogeneic Stem Cell Transplantation1 trial

Advanced Cancer1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Acute Graft Versus Host Disease1 trial

Advanced Stage1 trial

Hematologic Malignancies1 trial

Acute Myeloid Leukemia1 trial

Ann Arbor Stage IIB Hodgkin Lymphoma1 trial

Stage III1 trial

Diffuse Cutaneous Systemic Sclerosis1 trial

Relapsed Classic Hodgkin Lymphoma1 trial

Advanced Hodgkin Lymphoma1 trial

CD30-Positive Neoplastic Cells Present1 trial

Adult T-Cell Leukemia/lymphoma1 trial

NK-Cell Lymphoma1 trial

Peripheral T-Cell Lymphoma1 trial

Recurrent Hodgkin Lymphoma1 trial

Lymphomatoid Papulosis1 trial

Cutaneous T-Cell Lymphoma/Mycosis Fungoides1 trial

Melanoma1 trial

Recurrent Follicular Lymphoma1 trial

Chronic Lymphocytic Leukemia1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News